Rucaparib Plus Ramucirumab With or Without Nivolumab in Advanced Gastric and Esophageal Adenocarcinoma
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
The study population is advanced gastric, gastroesophageal, and esophageal adenocarcinoma
participants who have failed upfront standard of care chemotherapy. The goal is to
demonstrate that Rucaparib plus Ramucirumab with or without Nivolumab has a higher response
rate than what has been reported for Ramucirumab in previously treated patients. Trial will
be a phase 1/2 trial. The Phase 1 portion will determine the recommended Phase 2 treatment
dose for the combination of Rucaparib plus Ramucirumab and Nivolumab and enroll approximately
6-9 participants. The Phase 2 portion of the study will involve 52 participants allocated
between two treatment groups comparing Rucaparib plus Ramucirumab with or without Nivolumab.
The participants will be selected based on the results of a screening HRD gene panel.